Zhou ShiYu, Tao Lili, Zhang Zheng, Zhang Zhenhui, An Shengli
Department of Biostatistics, School of Public Health (Guangdong Provincial Key Laboratory of Tropical Disease Research), Southern Medical University, Guangzhou, Guangdong, China.
Department of Critical Care Medicine, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Br J Clin Pharmacol. 2022 Jun;88(6):2747-2756. doi: 10.1111/bcp.15204. Epub 2022 Jan 14.
The mortality of critically ill patients undergoing mechanical ventilation (MV) is high and few strategies are available. We explored the relationship between ondansetron pre-treatment, the neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR), and mortality of ventilated patients in the intensive care unit.
We developed a retrospective cohort study that involved patients undergoing MV in the Multiparameter Intelligent Monitoring in Intensive Care IV (MIMIC-IV) database. Causal mediation analysis was conducted to assess the relationship of ondansetron use and mortality and to explore the potential causal pathway mediated by the NLR or PLR. The primary outcome was 28-day mortality.
A total of 17 927 eligible patients took part in the study (5665 had taken ondansetron before MV initiation and 12 262 patients had not). The odds ratio (OR) for 28-day mortality for ondansetron use uncorrelated with the mediator (NLR, PLR) was 0.72 (95% confidence interval [CI] = 0.64-0.81, P < .001). Ondansetron was also associated with a reduction in 28-day mortality after controlling for the mediator of NLR (OR = 0.98, 95% CI = 0.97-0.99, P < .01). For the indirect effect, the NLR could explain 13.47% (95% CI = 8.59-20.54%, P < .01) of the impact of ondansetron use on 28-day mortality. The proportion mediated increased to 21.50% (95% CI = 12.36-47.44%, P < .01) for 90-day mortality. Adjusted mediation analysis revealed no suggestion of a causal mediation pathway for this effect by the PLR (P = .12).
NLR may play substantial roles in the relationship between ondansetron pre-treatment before initiation of mechanical ventilation and the reduction of death risk in ventilated patients.
接受机械通气(MV)的重症患者死亡率很高,且可用的策略很少。我们探讨了昂丹司琼预处理、中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)与重症监护病房中接受机械通气患者死亡率之间的关系。
我们开展了一项回顾性队列研究,纳入了多参数智能重症监护IV(MIMIC-IV)数据库中接受机械通气的患者。进行因果中介分析以评估昂丹司琼使用与死亡率之间的关系,并探索由NLR或PLR介导的潜在因果途径。主要结局为28天死亡率。
共有17927例符合条件的患者参与了本研究(5665例在开始机械通气前使用了昂丹司琼,12262例患者未使用)。与中介因素(NLR、PLR)无关的昂丹司琼使用的28天死亡率的比值比(OR)为0.72(95%置信区间[CI]=0.64-0.81,P<.001)。在控制NLR中介因素后,昂丹司琼也与28天死亡率降低相关(OR=0.98,95%CI=0.97-0.99,P<.01)。对于间接效应,NLR可解释昂丹司琼使用对28天死亡率影响的13.47%(95%CI=8.59-20.54%,P<.01)。对于90天死亡率,中介比例增至21.50%(95%CI=12.36-47.44%,P<.01)。校正中介分析未显示PLR对该效应存在因果中介途径(P=0.12)。
NLR可能在机械通气开始前昂丹司琼预处理与降低接受机械通气患者死亡风险之间的关系中发挥重要作用。